The complexities in system building strategies — The case of personalized cancer medicines in England

Abstract Novel technologies often face difficulties in market uptake, especially when they differ significantly from already established technologies. In some cases, like personalized medicine, new technologies are composed of a number of parallel emerging technologies – in our case therapeutics and corresponding diagnostics – that are heavily co-dependent and cannot diffuse without each other. Therefore, actors in an innovation system need to engage themselves in complex system building strategies in order to create a more favorable environment for their emerging technologies. The bodies of literature on system building and innovation ecosystems have little overlap so far. In this article, we show how system building in a technological innovation system depends on different framework conditions in creating a market for personalized cancer therapeutics and corresponding companion diagnostics in England — such as technological complementarities, timing strategies and organizational complexity. Using this case we illustrate how notions from the literature on innovation ecosystems can complement the current system building literature.

[1]  Stefan Kuhlmann,et al.  Functions of innovation systems: A new approach for analysing technological change , 2007 .

[2]  R. Tuma Trastuzumab trials steal show at ASCO meeting. , 2005, Journal of the National Cancer Institute.

[3]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Staffan Jacobsson,et al.  Innovation systems: analytical and methodological issues , 2002 .

[5]  Björn A. Sandén,et al.  A framework for analysis of multi-mode interaction among technologies with examples from the history of alternative transport fuels in Sweden , 2011 .

[6]  Staffan Jacobsson,et al.  Transforming the Energy Sector : The evolution of technological systems in renewable energy technology , 2004 .

[7]  Ozgur Dedehayir,et al.  Dynamics of reverse salience as technological performance gap: An empirical study of the personal computer technology system , 2008 .

[8]  D. B. Montgomery,et al.  First‐mover advantages , 1988 .

[9]  W. Boon Demanding Dynamics - Demand articulation of intermediary organisations in emerging pharmaceutical innovations , 2003 .

[10]  Wim Turkenburg,et al.  Accelerating the deployment of carbon capture and storage technologies by strengthening the innovation system , 2010 .

[11]  Neil Rubens,et al.  A Network Analysis of Investment Firms as Resource Routers in Chinese Innovation Ecosystem , 2011, J. Softw..

[12]  T. Hellevik,et al.  Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation , 2014, Front. Oncol..

[13]  Lars Coenen,et al.  Sustainability transitions in the making: A closer look at actors, strategies and resources , 2012 .

[14]  Ron Adner,et al.  Value Creation in Innovation Ecosystems: How the Structure of Technological Interdependence Affects Firm Performance in New Technology Generations , 2009 .

[15]  Marko P. Hekkert,et al.  Innovation Studies Utrecht ( ISU ) Working Paper Series Understanding the build-up of a Technological Innovation System around Hydrogen and Fuel Cell Technologies , 2009 .

[16]  Staffan Jacobsson,et al.  Analyzing the functional dynamics of technological innovation systems: A scheme of analysis , 2008 .

[17]  M. Boysen,et al.  Erlotinib for the treatment of non-small-cell lung cancer. , 2009, The Lancet. Oncology.

[18]  Charles Edquist,et al.  Systems of innovation perspectives and challenges , 2004 .

[19]  Staffan Jacobsson,et al.  The emergence and troubled growth of a 'biopower' innovation system in Sweden , 2008 .

[20]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[21]  B. Truffer,et al.  Sustainability transitions: An emerging field of research and its prospects , 2012 .

[22]  C. Freeman Technology policy and economic performance : lessons from Japan , 1987 .

[23]  R. Laing,et al.  HER2 testing in the UK: consensus from a national consultation , 2007, Journal of Clinical Pathology.

[24]  Jochen Markard,et al.  Technological innovation systems and the multi-level perspective: Towards an integrated framework , 2008 .

[25]  Bengt-Åke Lundvall,et al.  National Systems of Innovation: towards a theory of innovation and interactive learning London: Pint , 1995 .

[26]  C Proudlove,et al.  Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. , 2010, Health technology assessment.

[27]  Ron Adner Match your innovation strategy to your innovation ecosystem. , 2006, Harvard business review.

[28]  James F. Moore The Death of Competition: Leadership and Strategy in the Age of Business Ecosystems , 1996 .

[29]  Susanne Durst,et al.  Success factors of innovation ecosystems - Initial insights from a literature review , 2013 .

[30]  Staffan Jacobsson,et al.  In Search of Useful Public Policies — Key Lessons and Issues for Policy Makers , 1997 .

[31]  J. Islas,et al.  Getting round the lock-in in electricity generating systems: the example of the gas turbine , 1997 .

[32]  D. Miles,et al.  Safety and efficacy of the combination of trastuzumab with docetaxel for HER2‐positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK , 2004, International journal of clinical practice.

[33]  S. Nambisan,et al.  Entrepreneurship and strategic thinking in business ecosystems , 2012 .

[34]  Jane Fridlyand,et al.  Considerations for the successful co-development of targeted cancer therapies and companion diagnostics , 2013, Nature Reviews Drug Discovery.

[35]  Glyn Elwyn,et al.  Putting patients first , 2012, BMJ : British Medical Journal.

[36]  J. Ashton-Chess,et al.  Market access challenges in the EU for high medical value diagnostic tests. , 2011, Personalized medicine.

[37]  F. Geels From sectoral systems of innovation to socio-technical systems: Insights about dynamics and change from sociology and institutional theory , 2004 .

[38]  R.A.A. Suurs,et al.  Motors of sustainable innovation : Towards a theory on the dynamics of technological innovation systems , 2009 .

[39]  I. Ellis,et al.  Recommendations for HER2 testing in the UK , 2000, Journal of clinical pathology.

[40]  Charles Edquist,et al.  Systems of Innovation Approaches - Their Emergence and Characteristics , 2013 .

[41]  Michael E. Holmes,et al.  Organizational Change and Innovation Processes: Theory and Methods for Research , 2000 .

[42]  C. Edquist Systems of Innovation: Technologies, Institutions and Organizations , 1997 .

[43]  D De Ruysscher,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[45]  Cristina Chaminade,et al.  Rationales for Public Policy Intervention in the Innovation Process: Systems of Innovation Approach , 2010 .

[46]  Marshall Scott Poole,et al.  Methods for Studying Innovation Development in the Minnesota Innovation Research Program , 1990 .

[47]  Jochen Markard,et al.  Creating and shaping innovation systems: Formal networks in the innovation system for stationary fuel cells in Germany , 2011 .

[48]  M. Hekkert,et al.  Innovation Studies Utrecht ( ISU ) Working Paper Series Systemic instruments for systemic innovation problems : a framework for policy makers and innovation scholars , 2011 .

[49]  F. Olleros Emerging Industries and the Burnout of Pioneers , 1986 .

[50]  H. Rohracher,et al.  Legitimizing research, technology and innovation policies for transformative change , 2012 .

[51]  Jochen Markard,et al.  Actor-oriented analysis of innovation systems: exploring micro–meso level linkages in the case of stationary fuel cells , 2008, Technol. Anal. Strateg. Manag..

[52]  Raghu Garud,et al.  Institutional Entrepreneurship as Embedded Agency: An Introduction to the Special Issue , 2007 .

[53]  J. F. Moore,et al.  Predators and prey: a new ecology of competition. , 1993, Harvard business review.

[54]  F. Geels Technological transitions as evolutionary reconfiguration processes: a multi-level perspective and a case-study , 2002 .

[55]  B. Carlsson,et al.  On the nature, function and composition of technological systems , 1991 .

[56]  Staffan Jacobsson,et al.  Opportunities for and limits to Academics as System builders—The case of realizing the potential of gasified biomass in Austria , 2009 .

[57]  J. T. Jørgensen,et al.  Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects , 2014, Front. Oncol..

[58]  R. Comis,et al.  The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. , 2005, The oncologist.

[59]  Jochen Markard,et al.  Context matters: How existing sectors and competing technologies affect the prospects of the Swiss Bio-SNG innovation system , 2011 .

[60]  Marko P. Hekkert,et al.  Explaining the failure of the Dutch innovation system for biomass digestion : A functional analysis , 2007 .

[61]  M. Hekkert,et al.  Networks and network resources in technological innovation systems: Towards a conceptual framework for system building , 2012 .

[62]  A. Hedgecoe,et al.  The Politics of Personalised Medicine: Pharmacogenetics in the Clinic , 2004 .